• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AbbVie (ABBV) Stock May Be 41% Undervalued Following Migraine Trial Win

    Simply Wall St·09/23/2026 11:26:37
    Listen to the news

    AbbVie has delivered a powerful 5 year run, while continuing to invest heavily in new drugs across immunology, neuroscience and aesthetics. This raises a straightforward question for you as a shareholder or potential buyer: Does the current share price around recent highs line up with what the business can reasonably generate in cash over time, once those pipelines and acquisitions are paid for?

    • AbbVie shares have returned 196.8% over the past 5 years, which puts real pressure on the underlying cash flows to justify how far the valuation has come.
    • Positive trial results for atogepant in menstrual migraine, new approvals for RINVOQ in pediatric arthritis and the Apogee acquisition may support future cash generation, but they also shape when those cash inflows arrive and how much investment is required along the way.
    • What if you looked at AbbVie through its earnings instead? See why AbbVie's 74.7x P/E tells a different valuation story.

    The issue now is whether AbbVie’s current market price is adequately backed by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.

    If you want to stress test whether AbbVie’s cash flow story and recent news flow justify today’s price in context, compare it against a broader set of 29 high quality undervalued stocks

    Does AbbVie Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity framework that looks at what AbbVie could return to shareholders after debt and reinvestment. On the latest numbers, the group generated trailing twelve month free cash flow of about $18.3b. The model then assumes that free cash flow grows over time rather than shrinking, with projections reaching the mid 30s to low $40b range by the mid 2030s in dollar terms.

    Those projected cash flows, when discounted back, point to an intrinsic value that the DCF suggests is substantially above the current share price of $265.21. Because the recent positive Phase 3 LUNA results for atogepant and the planned label expansion would, if approved, add another potential source of recurring cash inflows, the market’s current pricing arguably still trails what the cash flow profile in the model is set up to support. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.

    The AbbVie Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives for AbbVie pick up where the DCF puzzle leaves off. They spell out which future paths for AbbVie’s growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. Each one treats fair value as a clear, testable hypothesis about the business that you can track over time on the Community page.

    One of the top community narratives on AbbVie: roughly fairly valued

    "The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products..."

    Discover why this Narrative puts AbbVie at roughly fairly valued.

    Before Acting On AbbVie’s Valuation, One More Piece Of The Puzzle Matters

    Cash flows and trial news only tell part of the story for AbbVie, because the people setting priorities and how they are rewarded can tilt long term outcomes in ways this valuation alone cannot show. See who runs AbbVie and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.